Melanotan II: Tanning & Beyond

Category: Protocols Type: Protocol Read Time: 16 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/melanotan-ii-protocol

Educational content only. Not medical advice. Consult a licensed healthcare provider before starting any protocol. Melanotan II has been associated with mole darkening and rare serious side effects; baseline dermatological assessment is strongly advised.

Overview

Melanotan II (MT-II, MT2, also written Melanotan-2) is a synthetic cyclic analog of alpha-melanocyte stimulating hormone (α-MSH). It was originally developed in the 1980s at the University of Arizona — by a research group including Hadley, Levine, and colleagues — with the rather elegant idea of preventing skin cancer by inducing protective pigmentation before UV exposure rather than after. The thinking: if people who tan easily get less sunburn, why not give light-skinned individuals a way to mount a tan without burning first?

The compound that emerged is a small, potent peptide that binds promiscuously across the melanocortin receptor family — MC1R (pigmentation), MC3R and MC4R (appetite, sexual function, metabolic effects), and MC5R (exocrine gland activity). That receptor promiscuity is both the reason MT-II "does so much" and the reason it has more side effects than a tan-only drug would have.

A few things worth being clear about up front:

• MT-II is NOT FDA-approved for any human use. It is sold only as a "research chemical" in the United States.
• The UK and Australia have explicitly banned its sale to consumers. The EU classifies it as an unlicensed medicine.
• The afamelanotide drug Scenesse — a longer-acting MC1R agonist approved for erythropoietic protoporphyria — is the closest thing to a sanctioned cousin, and it is prescription-only.
• Melanotan I (afamelanotide) is MC1R-selective; Melanotan II is not. That selectivity difference explains why MT-II causes flushing, nausea, and erections while afamelanotide largely does not.

This guide covers what users actually do with MT-II, what the side effect profile really looks like, and the safety steps that anyone considering this peptide should not skip.

Mechanism of Action

MT-II is an agonist at the melanocortin receptors. Activation produces different downstream effects depending on which receptor — and which tissue — is involved.

MC1R — Pigmentation

MC1R sits on melanocytes in the skin. When activated by α-MSH (or MT-II), the receptor signals via cyclic AMP to upregulate tyrosinase and shift melanin synthesis from pheomelanin (red/yellow) toward eumelanin (brown/black). Eumelanin is the photoprotective form. This is the "tanning" pathway, and it is the same pathway that produces a natural tan after UV exposure — MT-II just primes melanocytes to respond more vigorously.

MC3R / MC4R — Central Effects

MC3R and MC4R are expressed heavily in the hypothalamus and brainstem. Activation produces:

• Appetite suppression (MC4R is a major satiety signal — loss-of-function mutations cause severe obesity)
• Sexual arousal and erection in men (the basis for bremelanotide / PT-141, an MC4R-selective drug)
• Nausea and flushing (an unfortunately common consequence of MC4R signaling in the brainstem)

MC5R — Exocrine

Less clinically prominent, but contributes to sebum production and may explain occasional reports of skin oiliness.

The net pharmacology: MT-II is a fast, broad melanocortin agonist. It will pigment the skin, but it will also reach into appetite, sexual, and autonomic circuits whether you want it to or not.

Loading vs Maintenance Phase

MT-II protocols are organized around two phases: a loading phase to build pigmentation, and a maintenance phase to preserve it. Without UV exposure, neither phase produces a meaningful tan — see the next section.

Notes on titration:

• Start low. A single 1 mg dose in a first-time user reliably produces nausea, flushing, and sometimes vomiting. Users who titrate from 100-250 mcg upward report dramatically better tolerance.
• Evening dosing (or with food) is standard, because nausea peaks 1-3 hours post-injection and sleeping through it is the most practical workaround.
• Subcutaneous injection is the standard route. Insulin syringes (29-31 gauge) into abdominal fat is typical.
• Some users report success with intranasal MT-II, but bioavailability is variable and dose control is poor.

UV Exposure Protocol

This is the section most casually written guides skip, and it is the one that matters most.

MT-II without UV exposure does not produce a tan. The peptide primes melanocytes — it does not bypass them. Melanogenesis still requires the UV signal (or, less efficiently, blue light) to fully activate. Users who inject MT-II for weeks without sun or UV bed exposure typically see slight darkening of moles, the lips, and the genital area, but minimal overall pigmentation change.

A reasonable approach:

• During loading, begin short, controlled UV exposures — natural sun in the morning or late afternoon, or brief tanning bed sessions (5-10 minutes, lower-intensity beds). The goal is to trigger melanogenesis without burning.
• Stop the moment skin pinks. Burning under MT-II still causes DNA damage. The peptide builds a base tan faster, which means less total UV is needed to reach a given color — not that UV becomes safe.
• Maintenance UV of 1-2 short sessions per week typically preserves color once the base tan is established.

The honest framing: MT-II shifts the UV-dose-to-tan curve to the left. You get more pigmentation per unit of UV. That is a real reduction in burn risk if you reduce UV exposure to match — and not a benefit at all if users simply log more total UV time because they tan faster.

There is no published evidence that MT-II reduces skin cancer risk in humans. The original Arizona hypothesis remains a hypothesis.

Expected Outcomes

Timeline based on user reports — outcomes vary substantially by baseline skin type (Fitzpatrick I-VI):

• Week 1-2 (loading + UV): First visible darkening, typically on face, shoulders, and existing moles. Freckles may appear or darken.
• Week 3-4: Base tan established. Skin tone noticeably deeper than baseline.
• Week 5-8: Tan deepens further with continued maintenance. Lips, nipples, and genital skin darken disproportionately (high melanocyte density).
• Post-cycle: Tan persists 2-3 months after stopping injections, gradually fading as melanocytes turn over. New moles or freckles that appeared during the cycle may not fully fade.

Fitzpatrick I (very fair, never tans) users sometimes report the most dramatic visible change. Fitzpatrick V-VI users may see little benefit, since baseline eumelanin is already high.

Side Effects & Safety

This is the section users skim and later regret skimming. MT-II's side effect profile is significant and worth knowing in advance.

Very Common

• Nausea. Reported by the majority of users, especially during loading. Peaks 1-3 hours post-injection. Mitigations: evening dosing, food before injection, dose titration, antihistamines or ondansetron in some users. Some people simply do not tolerate it.
• Facial flushing. Warm, red, sometimes blotchy. Usually resolves within an hour.
• Loss of appetite. A common "side effect" that some users actually seek out. Can be significant — multi-pound weight loss during loading is reported.
• Spontaneous erections (men). Especially during the first hour after injection. This is a direct MC4R effect and is the same mechanism behind PT-141. It is dose-dependent and frequently uncomfortable rather than welcome.
• Yawning, stretching, mild fatigue. Classic melanocortin-mediated symptoms.

Common but Important

• Darkening of existing moles. Nearly universal. Moles become more prominent and darker. This is the side effect that matters most clinically — see the next section.
• New freckles or lentigines. Especially on sun-exposed skin. Many do not fully fade after cycling off.
• Injection site reactions. Mild redness, occasional bruising.

Rare but Serious

• Rhabdomyolysis. A small number of case reports describe muscle breakdown following MT-II use, sometimes with renal involvement. Mechanism unclear.
• Posterior reversible encephalopathy syndrome (PRES) and renal/cerebral events. Isolated case reports exist.
• Melanoma reports. There are published cases of melanoma diagnosed in MT-II users, including changes in pre-existing moles. Causation versus correlation is unresolved — the same users were typically also pursuing increased UV exposure — but the combination of stimulated melanocyte activity plus UV exposure is biologically plausible as a risk factor.

Contraindications (use prohibited or strongly discouraged)

• Personal or family history of melanoma or atypical mole syndrome
• Numerous moles, especially atypical (dysplastic nevi)
• Pregnancy or breastfeeding
• Active cardiovascular disease (flushing and pressor effects)
• Pheochromocytoma
• Children, adolescents

Mole Monitoring

If a reader takes one thing from this guide, it should be this section.

MT-II reliably stimulates melanocytes — including melanocytes in existing moles. Moles darken, sometimes change shape, and occasionally develop irregular borders. Distinguishing benign MT-II-induced mole change from early melanoma is not something to attempt at home.

Standard precautions for anyone considering MT-II:

1. Baseline full-body skin exam with a board-certified dermatologist before starting. Photograph and document all moles. Many dermatologists offer total body photography (mole mapping) for high-risk patients.
2. Annual or biannual follow-up. More frequent if you have many moles or any history of skin cancer in family.
3. Watch for ABCDE changes: Asymmetry, Border irregularity, Color variation, Diameter > 6mm, Evolution over time.
4. Disclose MT-II use to your dermatologist. This affects how they interpret mole changes. Yes, they may judge you. The exam is more important than the judgment.
5. Excise anything suspicious. Lower threshold than baseline. Better to remove a benign mole than to miss a thin melanoma.

This is not a hedging disclaimer — it is the single most important safety practice associated with this peptide.

Stacking

Most MT-II users run it standalone. The melanocortin receptor effects already produce a lot of pharmacology in one molecule; piling on additional peptides increases side effect risk without clear benefit.

Generally Not Recommended

• MT-II + PT-141 (bremelanotide). Both activate MC4R. Combining them increases nausea, flushing, and pressor effects substantially, with no real synergy beyond what dose titration of either alone would achieve. Some users do this for stacked sexual effects; we do not recommend it.
• MT-II + GHRPs / GHRH analogs. No clear benefit, and the appetite suppression of MT-II combined with appetite stimulation from GHRPs makes nutritional tracking messy.

Sometimes Combined (with caution)

• Topical antioxidants / niacinamide. Reasonable supportive skincare during a cycle. Not a pharmacologic stack.
• Oral nicotinamide (NAM). Has independent evidence for reducing non-melanoma skin cancer risk in high-risk patients. Not an MT-II antidote, but a reasonable adjunct under dermatologist guidance.

There is no peptide stack that makes MT-II safer or more effective. The protocol that matters is the UV protocol and the dermatology protocol.

Cycling

Long-term safety data on MT-II in humans does not exist. Users have been self-administering it for roughly two decades, but no formal cohort study has tracked melanoma incidence, cardiovascular outcomes, or other long-term endpoints.

Pragmatic cycling pattern most commonly reported:

• Seasonal use. Load in spring, maintain through summer, discontinue in fall. This matches the practical pattern most users actually want — color when they will be wearing less clothing.
• Annual breaks. At least 3-6 months off per year. Allows melanocyte turnover and gives dermatology exams a clearer baseline.
• Total cumulative exposure unknown. Users with five or more years of repeated cycles exist; whether this is safe is unknown.

If a cycle produces persistent symptoms — ongoing nausea, fatigue, new mole changes, blood pressure changes — stop and reassess with a clinician.

Frequently Asked Questions

Q: Is Melanotan II legal? A: In the United States, MT-II is sold only as a research chemical and is not FDA-approved for human use. The UK and Australia have explicitly banned its consumer sale. Importing or selling MT-II for human use is illegal in many jurisdictions. Possession laws vary. Check your local regulations.

Q: Will MT-II give me skin cancer? A: There is no proof that MT-II causes melanoma, but isolated case reports exist and the biology is concerning — particularly when combined with UV exposure. The safest answer: nobody knows the long-term cancer risk, and dermatologic monitoring is non-negotiable.

Q: Does it work for all skin types? A: It works best for Fitzpatrick I-III (fair to medium). Fitzpatrick V-VI users typically see minimal change because baseline melanin production is already near maximum.

Q: Why am I always nauseous after injecting? A: Nausea is a direct central effect of MC4R activation in the brainstem. Mitigations: lower your dose, inject before bed, eat first, and consider titrating up slowly. Some people simply cannot tolerate MT-II — that is a real outcome.

Q: Does the tan go away after I stop? A: Yes, gradually. Pigmentation typically persists 2-3 months post-cycle and fades as skin cells turn over. New moles or freckles that appeared during the cycle often persist longer or permanently.

Q: Can women use MT-II? A: Yes, with the same caveats. Sexual side effects (genital arousal, flushing) occur in women as well, though typically less pronounced than spontaneous erections in men. Mole monitoring is equally important.

Q: Is intranasal MT-II safer than injection? A: Not really. Intranasal dosing is harder to control, often delivers less drug, and produces the same side effect profile when systemic absorption occurs. The route does not change the underlying receptor pharmacology.

Q: Will MT-II help me lose weight? A: It often suppresses appetite during loading, and some users do lose weight. This is not a weight loss tool — it is a side effect that disappears once you adjust to the peptide or stop using it. Using MT-II for weight loss is not advised given the side effect profile.

Related Content

• Peptide Safety Guide
• FDA Status Guide
• Peptide Legality Map 2026
• Reconstitution Cheat Sheet
• Injection Safety Checklist
• COA Reading Guide

Disclaimer: This content is for educational purposes only and is not medical advice. Melanotan II is not FDA-approved for human use and is sold only as a research chemical in the United States; it is banned for consumer sale in the United Kingdom and Australia. MT-II has been associated with mole darkening, new pigmented lesions, and rare serious side effects including rhabdomyolysis. Baseline and ongoing dermatologic assessment is strongly advised. Consult a licensed healthcare provider before starting any peptide protocol.

Source: https://peptides.nyc/learn/melanotan-ii-protocol